Astellas, MD Anderson ally in AML
Astellas Pharma Inc. and the University of Texas’ MD Anderson Cancer Center are teaming up to research and develop a treatment for acute myeloid leukemia (AML). (Apr.)
Tech Transfer Deals, May 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2015.
More from Deals
• By
Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.
• By
But the French major is still keen on early-stage M&A.
• By
Buy boosts the French major's immunology pipeline.
• By
Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.
More from Business
• By
In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.
• By
One Phase III trial hits but a second study misses by a mile.
• By
Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.